CCND1 and mantle cell lymphoma: The disease has two clinical presentations: common conventional MCL (cMCL) (90% of patients), which usually has an aggressive clinical course (SOX-11-positive cells and an unmutated IGHV), and an indolent clinical presentation (10% of patients), which generally presents as non-nodal leukemic phase (nnMCL) (SOX-11-negative, mutations of CCND1 and TLR2, and somatic hypermutation of IGHV) (2,3).